Personalis (NASDAQ:PSNL) Releases Earnings Results, Beats Estimates By $0.05 EPS

Personalis (NASDAQ:PSNL) announced its quarterly earnings data on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.05, FiscalAI reports. The business had revenue of $17.35 million for the quarter, compared to the consensus estimate of $17.12 million. Personalis had a negative net margin of 116.69% and a negative return on equity of 42.81%.

Here are the key takeaways from Personalis’ conference call:

• Personalis reported explosive clinical growth—6,183 tests in Q4 (329% YoY) and >16,000 tests in 2025—and announced Medicare coverage for breast and lung surveillance while guiding to 43,000–45,000 tests in 2026 and $78–80M in revenue.
• Biopharma MRD revenue is accelerating (≈240% YoY growth in 2025) as the company shifts from lower‑value legacy projects to higher‑value, multi‑year MRD partnerships, with MRD/pharma revenue guided to $20–21M in 2026.
• Margins and profitability will be pressured near term—gross margin compressed to 11% in Q4 and 22.7% for 2025, 2026 gross margin guide is 15–20%, and management expects a ~<$105M net loss and ~$100M cash burn in 2026 despite a $240M cash balance.
• Product innovation continued with the launch of the opt‑in Real‑Time Variant Tracker, now in an early access program, designed to detect therapy‑targetable and resistance mutations during MRD surveillance and potentially increase clinical utility and physician stickiness.

Personalis Price Performance

PSNL traded up $0.03 during trading hours on Friday, reaching $9.06. 3,153,023 shares of the stock traded hands, compared to its average volume of 1,149,165. The firm’s fifty day simple moving average is $8.83 and its two-hundred day simple moving average is $7.96. The company has a market cap of $804.53 million, a price-to-earnings ratio of -9.96 and a beta of 1.98. Personalis has a fifty-two week low of $2.83 and a fifty-two week high of $11.50.

Institutional Trading of Personalis

Hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc bought a new stake in shares of Personalis in the second quarter worth $30,000. BNP Paribas Financial Markets grew its holdings in Personalis by 406.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its position in shares of Personalis by 184.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,536 shares of the company’s stock worth $44,000 after purchasing an additional 3,592 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Personalis in the 1st quarter valued at about $47,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Personalis in the 4th quarter valued at about $82,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on PSNL shares. Morgan Stanley increased their price target on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Needham & Company LLC increased their target price on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday. Guggenheim lifted their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. Wall Street Zen downgraded shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, HC Wainwright raised their target price on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $11.14.

Personalis News Roundup

Here are the key news stories impacting Personalis this week:

• Positive Sentiment: Analyst price-target upgrade — Needham raised its PSNL target from $10 to $12 and reiterated a “buy” rating, implying meaningful upside from the current price and signaling increased analyst confidence. Benzinga
• Positive Sentiment: Operational growth target — Management outlined a plan targeting ~170% clinical test-volume growth for 2026 and highlighted acceleration from reimbursement and its MRD (minimal residual disease) strategy, which, if realized, would drive revenue and margin scaling. Seeking Alpha: Clinical Test Volume Growth
• Positive Sentiment: Q4 outperformance vs. EPS estimates — Personalis reported a $0.26 loss per share, beating consensus by $0.05, and delivered revenue roughly in line to slightly above expectations, which supports the near-term stock uplift. Press Release / Q4 Results
• Neutral Sentiment: Earnings call and transcript available — Management commentary and the full Q4 2025 call transcript provide more color on reimbursement progress, MRD commercialization cadence and margin plans; these details will determine whether the growth targets are credible. Yahoo Finance: Q4 Earnings Call Transcript
• Neutral Sentiment: Media coverage / snapshot pieces summarize results and strategy but add little new detail beyond the company release and call. SeattlePI: Q4 Snapshot
• Negative Sentiment: FY2026 revenue guidance set below street expectations — Personalis guided to roughly $78–$80M for FY2026 versus a consensus near $81M, introducing downside risk to near-term estimates and valuation. Yahoo Finance: Full Year Results & Guidance
• Negative Sentiment: Elevated short interest and persistent losses — Short interest rose ~21% in February to ~12.5% of float (an 8.6-day ratio), while the company remains unprofitable with negative margins and ROE, increasing volatility and downside risk if execution slips. MarketBeat: Short Interest & Stock Data
• Negative Sentiment: Conflicting coverage on revenue beat/miss — Some outlets flagged a revenue miss while company/other reports show a slight revenue beat; this mixed narrative can amplify intraday moves as investors parse which data source is authoritative. Zacks: Q4 Loss / Revenue Comment

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.